(Total Views: 704)
Posted On: 03/21/2022 8:19:35 PM
Post# of 148878
Remember back to around the First of this year when CYDY received its second unsigned love letter from the FDA whose apparent reason for the letter concerned a video? The non-apparent reason was a second warning to CYDY concerning how they handled information about LL.
Then remember the scheduled conference call in early January that was cancelled for no apparent reason? And then NP was relieved of his duties concerning CYDY, again for no apparent reason? Yes, I was puzzled also.
But I think all of these actions, done for "no apparent reasons" are directly related. I surmise that there were some very confidential and heated exchanges between the FDA and the CYDY Board. I'm paraphrasing here but I'd conjure up the FDA's message to CYDY was "if you think you're going to become an actual pharmaceutical company then you better start acting like one!".
I don't believe that CYDY's silence has anything to do with a buy-out or partnership. The only thing more important than that is an approval for LL for some indication. After an approval then go for the best deal.... but first get the approval.
So this silence, in my opinion, is self imposed so that only significant CYDY actions that have been approved or denied by the FDA will be released by CYDY. This is an 180 degree turn around from what had been happening before but the prior way wasn't working so well. With SA and the current Board Chairperson being well versed on what has to be shared with shareholders I'd guess we will get information from CYDY only after the FDA has effected some decision on LL.
So patience for us longs is in order. I believe in Leronlimab and its MOA. What CYDY is playing now is about the only hand left them. Finish the studies, get them Top-Lined and then fleshed out and submitted to the FDA who might take us seriously this time. In the mean time I'll just keep picking up these undervalued shares until The FDA affirms that Leronlimab is the real deal.
Then remember the scheduled conference call in early January that was cancelled for no apparent reason? And then NP was relieved of his duties concerning CYDY, again for no apparent reason? Yes, I was puzzled also.
But I think all of these actions, done for "no apparent reasons" are directly related. I surmise that there were some very confidential and heated exchanges between the FDA and the CYDY Board. I'm paraphrasing here but I'd conjure up the FDA's message to CYDY was "if you think you're going to become an actual pharmaceutical company then you better start acting like one!".
I don't believe that CYDY's silence has anything to do with a buy-out or partnership. The only thing more important than that is an approval for LL for some indication. After an approval then go for the best deal.... but first get the approval.
So this silence, in my opinion, is self imposed so that only significant CYDY actions that have been approved or denied by the FDA will be released by CYDY. This is an 180 degree turn around from what had been happening before but the prior way wasn't working so well. With SA and the current Board Chairperson being well versed on what has to be shared with shareholders I'd guess we will get information from CYDY only after the FDA has effected some decision on LL.
So patience for us longs is in order. I believe in Leronlimab and its MOA. What CYDY is playing now is about the only hand left them. Finish the studies, get them Top-Lined and then fleshed out and submitted to the FDA who might take us seriously this time. In the mean time I'll just keep picking up these undervalued shares until The FDA affirms that Leronlimab is the real deal.
(12)
(1)Scroll down for more posts ▼
